Imexon
 | |
| Clinical data | |
|---|---|
| ATC code | none |
| Identifiers | |
| |
| CAS Number |
59643-91-3  |
| PubChem (CID) | 68791 |
| ChemSpider |
62031  |
| UNII |
8F63U28T2V |
| KEGG |
D08932 |
| ECHA InfoCard | 100.056.199 |
| Chemical and physical data | |
| Formula | C4H5N3O |
| Molar mass | 111.102 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
| (what is this?) (verify) | |
Imexon (INN, trade name Amplimexon) is a substance that is being studied in the treatment of some types of cancer, including pancreatic, lung, breast, prostate, melanoma, and multiple myeloma. It is a cyanoaziridine derivative.
External links
- Amplimexon entry in the public domain NCI Dictionary of Cancer Terms
This article incorporates public domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".
This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.